+1(804) 937-3321
info@onecallpharmacy.com
Tesofensine is a potent, orally available investigational drug known for its mechanism as a Triple Monoamine Reuptake Inhibitor (TMRI). It simultaneously blocks the reuptake of Serotonin (5-HT), Norepinephrine (NE), and Dopamine (DA), significantly influencing appetite, energy balance, and satiety pathways in the brain.
Tesofensine is primarily an appetite suppressant that achieves its effect by modulating three major neurotransmitters:
Appetite Control: By boosting neurotransmitter levels in the central nervous system, particularly the hypothalamus, Tesofensine increases satiety signals, leading to hypophagia (reduced food intake).
Metabolic Effects: Research suggests it may also increase resting energy expenditure, indicating a dual action that supports a negative energy balance.
Targeting Obesity: Clinical trials showed the drug produced greater weight loss than many currently approved anti-obesity medications.
| Research Outcome | Clinical Data (24 Weeks) | Implication |
| Weight Loss Efficacy | Doses of 0.5 mg and 1.0 mg induced mean weight loss of 9.2% and 10.6%, respectively (compared to 2.0% for placebo). | Demonstrated high efficacy in treating general obesity. |
| Half-Life | Has an extremely long half-life of approximately 9 days (220 hours). | Requires careful, infrequent dosing to avoid accumulation and side effects. |
| Cardiovascular Risk | Caused a dose-dependent increase in heart rate (up to +7.4 bpm at 0.5 mg) and increases in blood pressure at higher doses. | Requires pre-existing heart or blood pressure conditions to be controlled before use. |
| Common Side Effects | Dry mouth, nausea, constipation, insomnia, and headache. | Side effects were generally mild-to-moderate but led to patient withdrawal in some trials. |
Development Status: Tesofensine (or a combination product, Tesomet, which includes metoprolol to counteract cardiovascular effects) is currently in Phase III clinical trials for obesity.
Legal Use: It is available only through compounding pharmacies with a prescription from a licensed healthcare provider for off-label or specialized use in obesity management.
WADA Status: Given its central nervous system activity and impact on performance-related monoamines, it would likely be considered a Prohibited Substance under WADA rules.
Reviews
There are no reviews yet.